High‐risk multiple myeloma: Redefining genetic, clinical, and functional high‐risk disease in the era of molecular medicine and immunotherapy
American Journal of Hematology · 2024-08 · 99 (8) · 1560-1575
DOI: 10.1002/ajh.27327 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 13.04.2024. Verfasst von Matthew J Rees und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 148 Literaturangaben.
Abstract (Originalsprache)
Multiple myeloma (MM) exhibits significant heterogeneity in its presentation, genetics, and treatment response. Despite therapeutic advances, some patients continue to relapse early (ER,
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Matthew J Rees, Shaji Kumar
Zitieren
APA
Rees, M. J., & Kumar, S. (2024). High‐risk multiple myeloma: Redefining genetic, clinical, and functional high‐risk disease in the era of molecular medicine and immunotherapy. American Journal of Hematology, 99(8), 1560-1575. https://doi.org/10.1002/ajh.27327
Vancouver
Rees MJ, Kumar S. High‐risk multiple myeloma: Redefining genetic, clinical, and functional high‐risk disease in the era of molecular medicine and immunotherapy. American Journal of Hematology. 2024;99(8):1560-1575. doi:10.1002/ajh.27327
BibTeX
@article{Rees2024,
author = {Rees, Matthew J and Kumar, Shaji},
title = {High‐risk multiple myeloma: Redefining genetic, clinical, and functional high‐risk disease in the era of molecular medicine and immunotherapy},
journal = {American Journal of Hematology},
year = {2024},
volume = {99},
number = {8},
pages = {1560--1575},
doi = {10.1002/ajh.27327}
}
EUVIMED